Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Use of liposomal amphotericin B in the treatment of disseminated coccidioidomycosis.

Literature DB >> 14620712

Use of liposomal amphotericin B in the treatment of disseminated coccidioidomycosis.

Suresh Antony¹, Delfina C Dominguez, Elsa Sotelo.

Abstract

Disseminated fungal infection is an important cause of morbidity and mortality, especially in immunocompromised hosts. Amphotericin B is an important part of the therapy and treatment of invasive and life-threatening mycoses. We present a case of disseminated coccidioidomycosis in a patient who was successfully treated with liposomal amphotericin B (AmBisome) on steroid therapy. It appears that liposomal amphotericin B may offer an alternative and safe option in the treatment of coccidioidomycosis when conventional amphotericin B cannot be used.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2003 PMID： 14620712 PMCID： PMC2594503

Source DB: PubMed Journal: J Natl Med Assoc ISSN： 0027-9684 Impact factor: 1.798

13 in total

1. Introduction to antifungal drugs.

Authors: W E Dismukes
Journal: Clin Infect Dis Date: 2000-04-20 Impact factor: 9.079

2. Progressive disseminated aspergillosis in a bone marrow transplant recipient: response with a high-dose lipid formulation of amphotericin B.

Authors: D P Kontoyiannis; B S Andersson; R E Lewis; I I Raad
Journal: Clin Infect Dis Date: 2001-02-23 Impact factor: 9.079

Review 3. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience.

Authors: Jill Adler-Moore; Richard T Proffitt
Journal: J Antimicrob Chemother Date: 2002-02 Impact factor: 5.790

Review 4. Overview of the lipid formulations of amphotericin B.

Authors: Bertrand Dupont
Journal: J Antimicrob Chemother Date: 2002-02 Impact factor: 5.790

Review 5. AmBisome (liposomal amphotericin B): a comparative review.

Authors: G W Boswell; D Buell; I Bekersky
Journal: J Clin Pharmacol Date: 1998-07 Impact factor: 3.126

6. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis.

Authors: A C Leenders; P Reiss; P Portegies; K Clezy; W C Hop; J Hoy; J C Borleffs; T Allworth; R H Kauffmann; P Jones; F P Kroon; H A Verbrugh; S de Marie
Journal: AIDS Date: 1997-10 Impact factor: 4.177

Review 7. Coccidioidomycosis--the airborne assault continues: an unusual presentation with a review of the history, epidemiology, and military relevance.

Authors: J W Olivere; P A Meier; S L Fraser; W B Morrison; T W Parsons; D M Drehner
Journal: Aviat Space Environ Med Date: 1999-08

Review 8. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.

Authors: M Tiphine; V Letscher-Bru; R Herbrecht
Journal: Transpl Infect Dis Date: 1999-12 Impact factor: 2.228

9. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group.

Authors: J N Galgiani; A Catanzaro; G A Cloud; R H Johnson; P L Williams; L F Mirels; F Nassar; J E Lutz; D A Stevens; P K Sharkey; V R Singh; R A Larsen; K L Delgado; C Flanigan; M G Rinaldi
Journal: Ann Intern Med Date: 2000-11-07 Impact factor: 25.391

Review 10. Liposomal amphotericin B, AmBisome.

Authors: R J Hay
Journal: J Infect Date: 1994-05 Impact factor: 6.072

3 in total